Category: News

Post

Aridis Pharmaceuticals, Inc. Appoints Alan H. Cohen, MD, as Senior Vice President of Clinical & Medical Affairs

SAN JOSE, Calif. – August 7, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced the appointment of Alan H. Cohen, MD, FAAP, FCCP, FAAAAI, FACAAI, as Senior Vice President of Clinical & Medical Affairs. Dr. Cohen has served as a Medical...

Post

Aridis Pharmaceuticals Enrolls First Patients in Global Pivotal Clinical Trial of Novel Monoclonal Antibody for Treating Acute Pneumonia

SAN JOSE, Calif. – August 2, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused...

Post

Aridis Pharmaceuticals, Inc. Presents Positive Phase 2a Safety and Efficacy Data of Salvecin™ (AR-301) in Patients with Severe Pneumonia Caused by Staphylococcus aureus During the 2017 ASM Microbe Congress

SAN JOSE, Calif. – June 05, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, presented top-line results of its Phase 2a trial of Salvecin (AR-301), its human monoclonal antibody used as an adjunct therapy for severe pneumonia caused by Staphylococcus aureus, at the...

Post

Aridis Pharmaceuticals, Inc. Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™

Award Supports Development Through Phase 2a Clinical Trials SAN JOSE, Calif. – January 09, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today it has secured a therapeutics development award from Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development affiliate...

Post

Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia

SAN JOSE, Calif. – January 5, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced positive clinical results from its Phase 1/2a study of AR-301, its fully human monoclonal antibody against Staphylococcus aureus alpha-toxin being evaluated as an adjunctive therapy in combination...

Post

Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference

SAN JOSE, Calif., September 21, 2016 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that CEO Vu Truong, Ph.D., will participate on a panel at the 2016 Anti-Infectives Rx Conference, held September 21, 2016, and hosted by Boston Biotech Conferences. Event Details Panel: Breakthroughs...

September 21, 2016September 21, 2016by In News
Post

Aridis Pharmaceuticals Expands the Company’s Clinical Advisory Board; Adds Three Industry Veterans with Unique Expertise in the Field

SAN JOSE, Calif., July 11, 2016 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the addition of three highly recognized experts, Bruno Francois, M.D., Jean Chastre, M.D., and Marin Kollef, M.D., F.A.C.P., F.C.C.P., to the company’s Clinical Advisory Board. These world-renowned authorities in hospital-acquired...